Inhibition of the IL-17A axis Protects against Immune-related Adverse Events while Supporting Checkpoint Inhibitor Anti-tumor Efficacy
Melissa G. Lechner(University of California, Los Angeles), Maureen A. Su(University of California, Los Angeles)
Cited by 2
Related Papers
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|416
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
|Journal of Clinical Oncology|2023|69
240 Distinct patterns of copy number aberrations in penile cancer
|European Urology Supplements|2016|1
Polyfunctional IL-21 <sup>+</sup> IFNγ <sup>+</sup> T follicular helper cells contribute to checkpoint inhibitor diabetes mellitus and can be targeted by JAK inhibitor therapy
|bioRxiv (Cold Spring Harbor Laboratory)|2024|1